S&P 500   3,975.16 (+0.60%)
DOW   32,438.56 (+0.60%)
QQQ   306.79 (+0.27%)
AAPL   156.73 (-0.43%)
MSFT   270.43 (-0.66%)
META   199.06 (+0.63%)
GOOGL   102.31 (+1.08%)
AMZN   98.35 (+0.65%)
TSLA   191.07 (+4.27%)
NVDA   260.20 (+0.46%)
NIO   9.18 (+4.91%)
BABA   83.12 (+2.62%)
AMD   95.62 (-1.23%)
T   18.55 (+0.32%)
F   11.68 (+4.47%)
MU   58.10 (+0.80%)
CGC   2.00 (+7.53%)
GE   92.17 (+2.50%)
DIS   95.69 (+1.56%)
AMC   4.34 (+1.64%)
PFE   40.74 (-0.17%)
PYPL   75.12 (+2.61%)
NFLX   303.84 (-0.42%)
S&P 500   3,975.16 (+0.60%)
DOW   32,438.56 (+0.60%)
QQQ   306.79 (+0.27%)
AAPL   156.73 (-0.43%)
MSFT   270.43 (-0.66%)
META   199.06 (+0.63%)
GOOGL   102.31 (+1.08%)
AMZN   98.35 (+0.65%)
TSLA   191.07 (+4.27%)
NVDA   260.20 (+0.46%)
NIO   9.18 (+4.91%)
BABA   83.12 (+2.62%)
AMD   95.62 (-1.23%)
T   18.55 (+0.32%)
F   11.68 (+4.47%)
MU   58.10 (+0.80%)
CGC   2.00 (+7.53%)
GE   92.17 (+2.50%)
DIS   95.69 (+1.56%)
AMC   4.34 (+1.64%)
PFE   40.74 (-0.17%)
PYPL   75.12 (+2.61%)
NFLX   303.84 (-0.42%)
S&P 500   3,975.16 (+0.60%)
DOW   32,438.56 (+0.60%)
QQQ   306.79 (+0.27%)
AAPL   156.73 (-0.43%)
MSFT   270.43 (-0.66%)
META   199.06 (+0.63%)
GOOGL   102.31 (+1.08%)
AMZN   98.35 (+0.65%)
TSLA   191.07 (+4.27%)
NVDA   260.20 (+0.46%)
NIO   9.18 (+4.91%)
BABA   83.12 (+2.62%)
AMD   95.62 (-1.23%)
T   18.55 (+0.32%)
F   11.68 (+4.47%)
MU   58.10 (+0.80%)
CGC   2.00 (+7.53%)
GE   92.17 (+2.50%)
DIS   95.69 (+1.56%)
AMC   4.34 (+1.64%)
PFE   40.74 (-0.17%)
PYPL   75.12 (+2.61%)
NFLX   303.84 (-0.42%)
S&P 500   3,975.16 (+0.60%)
DOW   32,438.56 (+0.60%)
QQQ   306.79 (+0.27%)
AAPL   156.73 (-0.43%)
MSFT   270.43 (-0.66%)
META   199.06 (+0.63%)
GOOGL   102.31 (+1.08%)
AMZN   98.35 (+0.65%)
TSLA   191.07 (+4.27%)
NVDA   260.20 (+0.46%)
NIO   9.18 (+4.91%)
BABA   83.12 (+2.62%)
AMD   95.62 (-1.23%)
T   18.55 (+0.32%)
F   11.68 (+4.47%)
MU   58.10 (+0.80%)
CGC   2.00 (+7.53%)
GE   92.17 (+2.50%)
DIS   95.69 (+1.56%)
AMC   4.34 (+1.64%)
PFE   40.74 (-0.17%)
PYPL   75.12 (+2.61%)
NFLX   303.84 (-0.42%)
NASDAQ:VBLT

Vascular Biogenics - VBLT Stock Forecast, Price & News

$0.14
+0.00 (+2.49%)
(As of 03/21/2023 10:48 AM ET)
Add
Compare
Today's Range
$0.13
$0.14
50-Day Range
$0.13
$0.19
52-Week Range
$0.10
$2.20
Volume
291,362 shs
Average Volume
4.88 million shs
Market Capitalization
$9.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.17

Vascular Biogenics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
3,704.6% Upside
$5.17 Price Target
Short Interest
Healthy
2.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.24mentions of Vascular Biogenics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars


VBLT stock logo

About Vascular Biogenics (NASDAQ:VBLT) Stock

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Stock News Headlines

Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Why Is Vascular Biogenics (VBLT) Stock Up 52%?
Vascular Biogenics Cutting About 35% of Staff >VBLT
VBL Therapeutics Announces Workforce Reduction
See More Headlines
Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Company Calendar

Last Earnings
11/15/2021
Today
3/21/2023
Next Earnings (Estimated)
5/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBLT
Previous Symbol
NASDAQ:VBLX
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.17
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+3,704.6%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-32,300,000.00
Net Margins
-4,465.93%
Pretax Margin
-4,909.42%

Debt

Sales & Book Value

Annual Sales
$660,000.00
Book Value
$0.32 per share

Miscellaneous

Free Float
65,474,000
Market Cap
$9.47 million
Optionable
Optionable
Beta
0.80

Key Executives

  • Dror Harats
    Chief Executive Officer & Director
  • Eyal Breitbart
    Senior Vice President-Research & Operations
  • Erez Feige
    Senior Vice President-Business Operations
  • Samuel I. Backenroth
    Chief Financial Officer
  • Tami Rachmilewitz
    Senior Vice President-Clinical Development













VBLT Stock - Frequently Asked Questions

Should I buy or sell Vascular Biogenics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VBLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VBLT, but not buy additional shares or sell existing shares.
View VBLT analyst ratings
or view top-rated stocks.

What is Vascular Biogenics' stock price forecast for 2023?

4 Wall Street analysts have issued twelve-month price objectives for Vascular Biogenics' shares. Their VBLT share price forecasts range from $5.00 to $5.50. On average, they predict the company's stock price to reach $5.17 in the next year. This suggests a possible upside of 3,799.4% from the stock's current price.
View analysts price targets for VBLT
or view top-rated stocks among Wall Street analysts.

How have VBLT shares performed in 2023?

Vascular Biogenics' stock was trading at $0.12 at the beginning of 2023. Since then, VBLT shares have increased by 10.4% and is now trading at $0.1325.
View the best growth stocks for 2023 here
.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 1,240,000 shares, an increase of 699.5% from the February 13th total of 155,100 shares. Based on an average trading volume of 4,340,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 2.8% of the shares of the company are short sold.
View Vascular Biogenics' Short Interest
.

When is Vascular Biogenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 16th 2023.
View our VBLT earnings forecast
.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) posted its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. The biopharmaceutical company earned $0.20 million during the quarter, compared to the consensus estimate of $0.20 million. Vascular Biogenics had a negative trailing twelve-month return on equity of 103.43% and a negative net margin of 4,465.93%. During the same quarter last year, the company earned ($0.12) EPS.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.38%), Belvedere Trading LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Vascular Biogenics?

Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $0.13.

How much money does Vascular Biogenics make?

Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $9.24 million and generates $660,000.00 in revenue each year. The biopharmaceutical company earns $-29,920,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.

This page (NASDAQ:VBLT) was last updated on 3/21/2023 by MarketBeat.com Staff